Boston, Massachusetts – The Food and Drug Administration (FDA) has raised concerns over Abiomed’s Impella Left Sided Blood Pumps, linking them to at least 49 deaths and over 120 serious injuries. This revelation has sparked investigations into the safety and efficacy of these cardiovascular medical devices. Abiomed, a company fully owned by Johnson & Johnson, has come under scrutiny for its handling of the risks associated with the device.
According to reports, the FDA has criticized Abiomed for failing to promptly notify the agency of the potential risk of the device perforating the walls of the heart. The company allegedly only added a brief mention of these risks to their website two years after the FDA expected to be informed. Consequently, the FDA issued a warning letter to Abiomed in September 2023, signaling the severity of the situation.
Individuals who receive temporary implantation of the Impella device are often in critical condition and require urgent medical attention. However, if the device malfunctions and perforates the heart or blood vessels, it can lead to emergency cardiac surgery with a low survival rate. This has raised concerns among health professionals and patients alike about the safety of these devices.
Legal action is now being considered against Abiomed for the injuries and fatalities related to the Impella heart pumps. The FDA has issued multiple recalls for the device due to various risks, including the potential for fractures and increased clotting risks. Victims of these incidents may have legal recourse to seek compensation for the damages suffered.
If you or a loved one has experienced adverse effects from an Abiomed Impella heart pump, it is crucial to act promptly to protect your legal rights. Professional legal firms are now investigating claims against Abiomed, seeking justice for those impacted by the device’s failures.
Scientific literature has documented cases of heart perforations linked to Impella devices, raising concerns about their overall safety compared to traditional blood pumps. With ongoing investigations and increased awareness of the risks associated with these devices, the medical community is expected to further scrutinize the use of Impella devices in cardiac procedures.